Thursday, March 4, 2021, 12:00 PM - 1:15 PM CT  -  Register to attend March 4►

 

Activity Description

Most healthcare providers are not likely to encounter a meaningful amount of PAH patients potentially leading to a gap in initial diagnosis. This interprofessional activity will focus on the diagnosis gap, individualized treatment strategies, and patient-centered care practices for managing PAH treatments. The activity will begin with foundational PAH pathophysiology, then include a deep dive into PAH therapies and the most recent data surrounding their uses. Faculty will also discuss important patient-centric adverse effect management and quality of life discussions.

Target Audience

The target audience for this activity includes pharmacists, nurses, physicians and physician assistants.

Learning Objectives

At the completion of this activity, the participant will be able to:

• Examine the underlying pathogenic pathways, progression, and presentation of pulmonary arterial hypertension (PAH)
• Compare and contrast current and emerging PAH treatments by mode of delivery, mechanism of action, adverse effects, and monitoring parameters
• Discuss strategies to manage iatrogenic and progression-related scenarios to improve quality of life for PAH patients

Faculty

James C. Coons, PharmD, FCCP, BCCP
Associate Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

Martha Kingman, DNP, FNP-C
Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan

CME/CE Accreditation

	ACPE Credit Designation (Pharmacist CE) ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-017-L01-P has been assigned to this live knowledge-based activity (initial release date 3-4-21). This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
	Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Physician Continuing Medical Education CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   Nursing Continuing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
	AAPA Credit Designation Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty and planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Dr. Coons has conducted contracted research for Pfizer and United Therapeutics; received consulting fees from Alnylam and Bristol Myers Squibb.
Dr. Kingman has received consulting fees from Actelion/J&J, Bayer, and United Therapeutics.
Dr. McLaughlin has conducted contracted research for and received consulting fees from Acceleron, Actelion, and United Therapeutics; received consulting fees from Altavant, Caremark, CiVi Biopharma, Gossamer Bio, and Liquidia ; conducted contracted research for Reata and Sonavie.
CCO and ProCE Staff have no relevant conflicts of interest to report.
 

Funding

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

    

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.